Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for AZN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
March 31, 2026 600.99M
December 31, 2025 172.78M
September 30, 2025 11.67M
June 30, 2025 3.100M
March 31, 2025 478.00M
December 31, 2024 -856.00M
September 30, 2024 77.00M
June 30, 2024 828.00M
March 31, 2024 -6.00M
December 31, 2023 -21.00M
September 30, 2023 -4.00M
June 30, 2023 -4.00M
March 31, 2023 -4.00M
December 31, 2022 -18.00M
September 30, 2022 -3.00M
June 30, 2022 -3.00M
March 31, 2022 -5.00M
December 31, 2021 -19.00M
September 30, 2021 -1.00M
June 30, 2021 -4.00M
March 31, 2021 -5.00M
December 31, 2020 -19.00M
September 30, 2020 -2.00M
June 30, 2020 -3.00M
March 31, 2020 -6.00M
Date Value
December 31, 2019 -22.00M
September 30, 2019 -8.00M
June 30, 2019 -3.484B
March 31, 2019 -11.00M
December 31, 2018 -10.00M
September 30, 2018 -8.00M
June 30, 2018 -2.00M
March 31, 2018 -14.09M
December 31, 2017 -13.00M
September 30, 2017 -7.00M
June 30, 2017 -6.00M
March 31, 2017 -17.00M
December 31, 2016 -7.00M
September 30, 2016 -17.74M
June 30, 2016 -3.951M
March 31, 2016 -17.82M
December 31, 2015 -13.00M
September 30, 2015 -10.00M
June 30, 2015 -5.00M
March 31, 2015 -15.00M
December 31, 2014 -15.31M
September 30, 2014 -8.469M
June 30, 2014 -57.36M
March 31, 2014 -197.85M
December 31, 2013 -214.00M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
GSK Plc 410.58M
Johnson & Johnson -138.00M
Eli Lilly & Co. 1.601B
Merck & Co., Inc. 714.00M
Novo Nordisk A/S 547.31M